BioMarin expands portfolio but faces debt and new competitive pressure
- BioMarin bought Amicus in April 2026 for about $4.8 billion, expanding its commercial portfolio.
- Management targets $1.4 billion in peak sales for Galafold and $220 million in cost savings.
- Total debt rose to roughly $4.3 billion after the Amicus close, introducing significant leverage.
- Voxzogo faces growing competitive pressure in the US, with about 15 percent of patients switching.
- A single international customer deferred a $70 million order, highlighting the risk of lumpy revenue.
Diversification with growing pressures
BioMarin is testing a new strategy. The April 2026 Amicus acquisition added Galafold for Fabry disease and Pombiliti plus Opfolda for late-onset Pompe disease. This gives BioMarin more products and less reliance on Voxzogo alone. Management laid out clear targets, aiming for $1.4 billion in peak sales for Galafold and $220 million in annual cost synergies by 2028.
The bull case points to a more profitable rare disease leader. If BioMarin grows Voxzogo, hits its peak sales targets for the acquired drugs, and achieves the $220 million in synergies, the combined cash flow will allow the company to rapidly pay down debt. Early updates show that Amicus cost synergies are tracking ahead of schedule.
The bear case centers on execution risk, debt, and new competition. Total debt sits at roughly $4.3 billion. Voxzogo is facing new pressure in the US market, with a switch rate to a competitor reaching 15 percent. Management announced they will stop reporting this switch metric going forward, raising transparency concerns. Furthermore, a recent $70 million order deferral highlights the vulnerability of the international revenue base.
The upcoming year requires proof of execution. Investors are watching to see if the Voxzogo switch rate stabilizes, whether the $70 million deferred order is realized in early 2027, and how the pending ITC patent case resolves in December 2026.
Rare diseases, high prices, small markets
BioMarin focuses entirely on rare genetic diseases. Because these patient groups are very small, the company relies on high per-patient pricing to recover development costs. This requires broad access agreements with insurers and government buyers.
Historically, the model worked well once a drug became the standard of care. Voxzogo, Vimizim, and Naglazyme built a strong base, generating a combined $560.2 million in the first quarter of 2026. The Amicus acquisition broadens this base significantly, bringing established enzyme therapies for Fabry and Pompe diseases.
However, this broader model comes with increased complexity. BioMarin must now manage a much larger debt load, integrate new sales teams, and handle more complex manufacturing. High reliance on large international orders also introduces quarter-to-quarter revenue lumpiness, as seen with recent order delays in the Middle East.
The drugs that drive the story
Voxzogo
Voxzogo treats achondroplasia and is a major growth driver. It faces a 15 percent competitive switch rate in the US and awaits a key FDA decision for hypochondroplasia in May 2027.
Galafold
Acquired from Amicus in April 2026, Galafold treats Fabry disease. Management believes it can reach $1.4 billion in peak sales.
Pombiliti and Opfolda
Also acquired from Amicus, this combination treats late-onset Pompe disease. BioMarin targets $1.2 billion in peak sales.
Vimizim
Vimizim treats MPS IVA and produced $210.2 million of net product revenue in early 2026. It provides steady cash flow.
Naglazyme
Naglazyme treats MPS VI and generated $130.1 million in early 2026. Manufacturing complexities have caused recent margin pressure.
BMN 820
BioMarin acquired US rights to BMN 820 for focal segmental glomerulosclerosis in April 2026. It is an early stage pipeline bet.
Q1 mix before Amicus
This mix uses first quarter 2026 net product revenue from the March 31, 2026 10-Q. It does not include Galafold or Pombiliti and Opfolda, because the Amicus deal closed after the quarter ended.
What could go wrong
Voxzogo loses market share
High impact · High oddsThe high price model is vulnerable to competition. Management noted that approximately 15 percent of US Voxzogo patients switched to a competitor, and the company will no longer report this metric.
Amicus integration misses targets
High impact · Medium oddsBioMarin spent about $4.8 billion on Amicus. If it fails to reach its peak sales targets or cannot achieve the $220 million in cost synergies, the deal will destroy value.
International order lumpiness
Medium impact · Medium oddsHigh reliance on large international orders introduces quarter-to-quarter revenue lumpiness. A recent $70 million order deferral highlighted this vulnerability.
Debt limits flexibility
High impact · Medium oddsTotal debt rose to roughly $4.3 billion after the Amicus close. The resulting interest expense could strain finances if the new commercial assets underperform.
Adverse patent rulings
High impact · Medium oddsAn ongoing ITC patent case creates near-term binary risk for the company's intellectual property. A final decision is expected in December 2026.
In one breath
What does BioMarin do?
BioMarin develops and sells medicines for rare genetic diseases. Its main products include Voxzogo, Vimizim, Naglazyme, and the newly acquired Amicus products.
Why did BioMarin buy Amicus?
The acquisition added Galafold for Fabry disease and Pombiliti plus Opfolda for late-onset Pompe disease. It diversifies revenue but added significant debt.
Is Voxzogo facing competition?
Yes. Management recently stated that about 15 percent of US patients switched to a competitor. The company will stop reporting this specific metric going forward.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near BioMarin Pharmaceutical Inc. in Finn's Biotechnology industry ranking.

